Acute promyelocytic leukemia after Stanford V plus radiotherapy for advanced Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 50, Issue 7, 2009, Pages 1214-1216

  Aversa, Savina Maria Luciana ^a   Trentin, Chiara ^a   Sorarů , Mariella ^b   Bona, Eros Di ^c   Marino, Dario ^a   Canova, Fabio ^a   Salvagno, Luigi ^d   Adami, Fausto ^e  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b Camposampiero Hospital   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

^d Vittorio Veneto Hospital   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD15 ANTIGEN; CD2 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD7 ANTIGEN; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLOOD EXAMINATION; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CHROMOSOME 15Q; CHROMOSOME 17Q; CHROMOSOME BAND; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CLINICAL PROTOCOL; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HODGKIN DISEASE; HUMAN; LEUKEMIA REMISSION; NEUTROPENIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; STANDARD V PLUS RADIOTHERAPY; TRISOMY 8;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DOXORUBICIN; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HODGKIN DISEASE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MECHLORETHAMINE; NEOPLASMS, RADIATION-INDUCED; PREDNISONE; REMISSION INDUCTION; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 68449090649     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902934910     Document Type: Article

References (15)

1. Diehl V, Engert A, Re D. New strategies for the treatment of advanced-stage Hodgkin's lymphoma. Hem Oncol Clin N Am 2007;21:897-914.
2. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief chemotherapy, Stanford V and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report. J Clin Oncol 1995;13:1080-1088.
3. Horning SJ, Williams J, Bartlett NL, et al. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group Pilot Study E1492. J Clin Oncol 2000;18:972-980.
4. Aversa SML, Salvagno L, Sorarù M, et al. Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease. Acta Haematol 2004; 112:141-147.
5. Abuzetun J, Loberizia F, Vose J, et al. The Stanford V regimen is effective in patients with good risk Hodgkin lymphoma but radiotherapy is a necessary component. Br J Haematol 2009;144:531-537.
6. Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans retinoic acid+idarubucina) in newly diagnostic acute promyelocytic leukemia: A Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996;88:1390-1398.
7. Pedersen-Bjergaard J, Klarskov Andersen M, Johansson B. Balanced chromosome aberrations in leukemia following chemotherapy with DNA-topoisomerase II inhibitors. J Clin Oncol 1998;16:1897-1898.
8. Mistry AR, Felix CA, Whitmarsh RJ, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005;352:1529-1538.
9. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment. J Clin Oncol 2000;18:498-509.
10. Hoffmann L, Moller P, Pedersen-Bjergaard J, et al. Therapy related acute promyelocytic leukemia with t(15,17)(q22,q12) following chemotherapy with drugs targeting DNA topoisomerase II: A report of two cases and a review of the literature. Ann Oncol 1995;6:781-788.
11. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colonystimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007;99:196-205.
12. Freedman MH, Bonilla MA, Fier C, et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood 2000;96:429-436.
13. Patt DA, Duan Z, Fang S, Hortobagyi GN, Giordano SH. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 2000;25:3871-3876.
14. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicincyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 2003;21:1195-1204.
15. Pulsoni A, Pagano L, Lo Coco F, et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumour: the GIMEMA experience. Blood 2002;100:1972-1976.